Skip to content

Quality of Life in Patients With Congenital Afibrinogenemia

Quality of Life in Patients With Congenital Afibrinogenemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03484065
Acronym
QualyAFIB
Enrollment
250
Registered
2018-03-30
Start date
2016-06-30
Completion date
2020-06-30
Last updated
2020-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Afibrinogenemia, Congenital

Keywords

Congenital fibrinogen disorders

Brief summary

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.

Detailed description

In this observational study, children and adults suffering from congenital afibrinogenemia confirmed by biology will be enrolled. All patients will receive a questionnaire on quality of life in their own language during a routine visit and filled out by the patient at home. A general questionnaire will be filled out by the patient's physician.

Interventions

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Congenital afibrinogenemia confirmed by biology (absence of circulating fibrinogen) and genotype

Exclusion criteria

* Lack of participant's consent * Patient unable to understand the questionnaire

Design outcomes

Primary

MeasureTime frameDescription
The influence of the afibrinogenemia on the patients' quality of life assessed by the Haemo-QoL SF questionnaire (for children) and the Haem-A-QoL questionnaire (for adult)At inclusionThe quality of life questionnaire includes item assessing: * Physical health * Feeling * View * Family * Friends * Others * Sport and school * Treatment * Perceived support * Dealing * Future * Relationship

Secondary

MeasureTime frameDescription
Impact of the afibrinogenemic patient's clinical phenotype on the patients' quality of lifeAt InclusionThe clinical phenotype will be assessed by a general questionnaire including data on: * Bleeding events * Bleeding events treatment * Thrombotic events * Thrombotic events treatment * Fibrinogen replacement (type of product and modality of replacement)

Countries

Algeria, Canada, Egypt, France, Germany, India, Italy, Japan, Kuwait, Lebanon, Morocco, Netherlands, Pakistan, Poland, Serbia, Slovakia, Spain, Switzerland, Tunisia, Turkey (Türkiye), United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026